XML 33 R18.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Major Customer: | 12 Months Ended
--- | ---
Dec. 31, 2015
Major Customer Disclosure [Abstract] |
Product,MajorCustomerandConcentrationofCreditRisk [Text Block] | Products, Major Customers and Concentrations of Credit Risks Our primary product groups are infusion therapy, critical care and oncology. The breakdown by market segment for the years ended December 31, 2015, 2014 and 2013 are as follows:
|  | 2015 |  | 2014 |  | 2013
Infusion therapy |  | $ | 244,746 |  |  | $ | 216,280 |  |  | $ | 221,192 |
Critical care |  | 54,312 |  |  | 55,074 |  |  | 54,328 |
Oncology |  | 41,447 |  |  | 36,651 |  |  | 36,857 |
Other |  | 1,163 |  |  | 1,255 |  |  | 1,339 |
|  | $ | 341,668 |  |  | $ | 309,260 |  |  | $ | 313,716 |
We sell products worldwide, on credit terms on an unsecured basis, as an OEM supplier, to independent medical supply distributors, and directly to the end customer. The manufacturers and distributors, in turn, sell our products to healthcare providers. For the years ended December 31, 2015, 2014 and 2013, we had worldwide sales to one manufacturer, Pfizer, of 36%, 36% and 39%, respectively, of consolidated revenue. As of December 31, 2015, and 2014, we had accounts receivable from Pfizer of 40% and 27%, respectively, of consolidated accounts receivable. Domestic sales accounted for 71%, 69% and 71% of total revenue in 2015, 2014 and 2013, respectively. International sales, which are determined by the destination of the product shipment, accounted for 29%, 31% and 29% of total revenue in 2015, 2014 and 2013, respectively. The table below presents our gross long-lived assets by country:
|  | As of December 31,
|  | 2015 |  | 2014
Mexico |  | $ | 53,462 |  |  | 51,554 |
Slovakia(1) |  | 5,480 |  |  | 16,643 |
Italy |  | 4,418 |  |  | 4,855 |
Germany |  | 671 |  |  | 638 |
Netherlands |  | 49 |  |  | — |
Australia |  | 35 |  |  | — |
Total foreign |  | $ | 64,115 |  |  | $ | 73,690 |
United States |  | 158,933 |  |  | 151,024 |
Worldwide total |  | $ | 223,048 |  |  | $ | 224,714 |
____________________________ (1) The decrease in Slovakia long-lived assets included an $8.2 million reclass of land and building to assets held for sale, which were subsequently impaired, see Note 6, Impairment of assets held for sale.

X
- Definition Major Customer [Abstract] + References No definition available. + Details
Name: | icui_MajorCustomerDisclosureAbstract
Namespace Prefix: | icui_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Product, Major Customer and Concentration of Credit Risk footnote + References No definition available. + Details
Name: | icui_ProductmajorcustomerandconcentrationofcreditriskTextBlock
Namespace Prefix: | icui_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration